selective CDK2 inhibitor (Cedilla Therapeutics)

N/A

Report date: 2026/01/07 10:32:03
NME

Base Information

Drug Nameselective CDK2 inhibitor (Cedilla Therapeutics)
Drug Alias NameCDK2-Cyclin E Precision Therapeutic (Cedilla)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCyclin-dependent kinase 2 inhibitorsG1/S-specific cyclin-E1 degraders
TargetsCyclin-dependent kinase 2G1/S-specific cyclin-E1
Therapy Area/IndicationsUterine NeoplasmsOvarian NeoplasmsStomach Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCedilla Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesBayer AG
Inactive CompaniesCedilla Therapeutics Inc
Active IndicationsUterine NeoplasmsOvarian NeoplasmsStomach Neoplasms +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A